Medical Licensing (MD/DO) · Independent exam preparation
Complex Family Planning Qualifying Examination: Clinical Decisions and Evidence Guide Study Guide
Practise complex contraceptive choices, early pregnancy assessment, abortion safety and evidence appraisal for ABOG's physician subspecialty qualifying exam.
By CertMedbry · Updated 15 October 2026
Choose contraception with complex comorbidities, distinguish unresolved pregnancy location from confirmed ectopic pregnancy, manage abortion complications and interpret research that informs access to care. This selective guide develops 60 clinical and analytical concepts across all four official domains. The complete ABOG competency outline defines the full examination scope; candidates should use it to identify additional competencies requiring study.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide address?
The target is the Complex Family Planning Qualifying Examination included in ABOG's 2026 Subspecialty Qualifying Examination bulletin. It belongs to voluntary physician subspecialty board certification. The subsequent oral Certifying Examination has a different assessment purpose and format; this guide's written drills address the qualifying stage.
How many questions are administered?
The 2026 bulletin specifies 230 single-best-answer multiple-choice questions. Prepare to select the best response to each clinical or analytical problem.
What language, item style and assessment skills should candidates expect?
The examination uses single-best-answer multiple-choice questions administered in English. It assesses information gathering, data interpretation, care selection and implementation, complications, and follow-up. This guide provides 20 original four-option practice questions; their option count and difficulty labels describe these learning exercises.
Where is the examination delivered, and how is an appointment scheduled?
The examination is delivered at Pearson VUE testing centers. After receiving ABOG authorization and scheduling instructions, arrange a testing-center appointment through Pearson VUE. Follow the candidate instructions for appointment availability, identification, arrival and testing-center procedures.
How should candidates plan for examination duration?
Use the CFP subspecialty candidate instructions and appointment confirmation to establish testing and arrival times. The approximately 3-hour-45-minute statement in the 2026 bulletin is labeled 'Specialty Qualifying Examination'; that wording does not establish the CFP subspecialty examination's duration.
Which blueprint applies, and what is its effective date?
Use ABOG's currently linked Complex Family Planning competency blueprint. Its four domains are Contraception; Early pregnancy assessment; Abortion; and Research, health policy and advocacy. The document does not state an explicit implementation or update date. Use the official blueprint listing to obtain the current outline.
ABOG subspecialty-certification blueprint listing · ABOG Complex Family Planning competency blueprint
How is coverage distributed when the blueprint gives no percentages?
The current outline supplies no numeric domain weights. This guide uses 21 contraception concepts, 12 early pregnancy assessment concepts, 18 abortion concepts and 9 research, policy and advocacy concepts. The questions and flashcards each use a 7/4/6/3 distribution. These proportions organize study and do not estimate official examination weighting. The official outline remains the full scope.
Which clinical guidance editions and jurisdictions inform the teaching?
Contraceptive eligibility and initiation teaching uses CDC's 2024 U.S. MEC and U.S. SPR. SFP recommendations support specialized abortion decisions; its 20–24-week cervical-preparation guidance is reaffirmed August 2026 and marked under revision. WHO's August 2025 second edition reports a limited change to Recommendation 22 remarks. FDA labeling supports the identified early medication-abortion regimen, pharmacology and warnings. FIGO guidance informs postmolar surveillance. These clinical recommendations do not establish the law in a particular jurisdiction.
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 · SFP Cervical Preparation for Dilation and Evacuation at 20–24 Weeks · WHO Abortion Care Guideline, Second Edition · FDA Mifeprex Prescribing Information, Revised January 2023 · IJGO-171-78.PMC12411817.pdf
This guide addresses ABOG's written Complex Family Planning Qualifying Examination for physician subspecialty certification. The oral Certifying Examination is a separate stage. The guide, questions and flashcards are independent educational materials, without ABOG endorsement or claims to reproduce secure examination content.
Outline used: ABOG 2026 Subspecialty Qualifying Examination bulletin, opened live on 2026-10-09, together with the currently linked CFP competency blueprint preserved in trusted frozen issuer evidence retrieved on 2026-10-08. The blueprint URL contains /2026/, but its readable text states neither an explicit effective/update date nor numeric domain weights. The workbook label names the subspecialty certification broadly; this preview maps specifically to its written Qualifying Examination, distinguished from the oral Certifying Examination. The assigned slug is preserved. No announced newer CFP blueprint was found in live searches.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Contraceptionnot stated
1.How should reproductive goals guide contraceptive counseling?
Person-centered counseling starts with the patient's reproductive goals, preferences and experience, including whether contraception is wanted at all. Effectiveness matters alongside bleeding, privacy, control, adverse effects and ease of discontinuation. Explain medically appropriate choices without treating uptake of a particular method as success. A patient who understands a highly effective option and declines it has made a valid decision; counseling should support that decision and preserve access to alternatives.
Apply it
A patient wants pregnancy prevention but declines an implant because unpredictable bleeding would interfere with religious practices. Explore acceptable bleeding patterns and daily routines, then compare suitable alternatives without repeatedly promoting the implant.
Common pitfall: Ranking methods solely by effectiveness can turn counseling into pressure. A medically eligible method is an option, not an obligation or a preferred outcome.
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
2.What do U.S. MEC categories mean for a treatment decision?
U.S. MEC categories describe safety for a specific method and condition. Category 1 means no restriction; category 2 means advantages generally outweigh theoretical or proven risks. Category 3 means risks usually outweigh advantages, and category 4 indicates unacceptable health risk. Categories are neither effectiveness rankings nor numerical risk estimates. Read accompanying clarifications, distinguish initiation from continuation when specified, and consider the patient's exact diagnosis rather than applying a broad disease label.
Apply it
A clinician sees category 3 beside a requested method and calls it absolutely contraindicated. Reassess the condition-specific clarification, available alternatives and clinical circumstances; category 4, rather than category 3, denotes unacceptable risk.
Common pitfall: Adding category numbers across several conditions creates a meaningless score. Evaluate each relevant condition and its interaction with the method instead of doing arithmetic.
3.Why does migraine with aura change estrogen eligibility?
Migraine with aura and estrogen-containing contraception each raise concern about ischemic stroke. CDC classifies combined hormonal contraception as category 4 for migraine with aura. Accurate history matters: aura is a focal neurologic symptom, not simply severe headache, nausea or light sensitivity. The restriction applies to combined pills, patches and rings because all contain estrogen. Evaluate new or substantially changed headaches and discuss eligible methods without estrogen based on other medical conditions.
Apply it
A patient requesting a vaginal ring describes a shimmering visual field defect before headaches. Recognize a possible aura history, clarify its features and select an appropriate estrogen-free option rather than assuming vaginal delivery avoids stroke risk.
Common pitfall: Changing from a combined pill to a combined ring does not remove estrogen exposure. Route alone does not overcome the migraine-with-aura restriction.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives
4.Why is current nephrotic syndrome important before prescribing estrogen?
Current nephrotic syndrome is associated with increased thrombosis risk, making the additional thrombotic effects of combined hormonal contraception unacceptable under U.S. MEC category 4. This is a condition-specific judgment, not a conclusion that every contraceptive method is unsafe in kidney disease. Assess the precise renal condition, dialysis status, associated hypertension and other comorbidities. Method-specific tables are necessary because progestin methods and intrauterine methods do not all receive the same classification.
Apply it
A patient with active nephrotic syndrome requests a combined patch because pills are inconvenient. Explain the estrogen-related thrombotic concern and compare eligible alternatives after reviewing the patient's renal status and associated conditions in detail.
Common pitfall: A transdermal route does not eliminate estrogen-associated thrombosis risk. Also avoid assuming that all progestin methods share identical eligibility in chronic kidney disease.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives · CDC Summary of U.S. MEC Classifications, 2024
5.Which contraceptive choices resist enzyme-inducing antiseizure interactions?
Certain antiseizure medicines, including carbamazepine and phenytoin, induce drug-metabolizing enzymes and can reduce the effectiveness of several systemic hormonal contraceptives. The concern is inadequate hormone exposure, not simply additive adverse effects. Copper and levonorgestrel IUD effectiveness is not reduced by these medicines; depot medroxyprogesterone also has different interaction guidance from pills and implants. Identify the actual drug because antiseizure medicines are not interchangeable in their contraceptive interactions.
Apply it
A patient taking carbamazepine wants a reversible method with little user effort. Compare copper and levonorgestrel IUDs using bleeding preferences and uterine eligibility, explaining why enzyme induction does not undermine these choices.
Common pitfall: Do not classify every antiseizure medicine as an enzyme inducer. Conversely, assuming every progestin method escapes induction can overlook reduced pill or implant effectiveness.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives · CDC Appendix B: Classifications for Intrauterine Devices · CDC Summary of U.S. MEC Classifications, 2024
6.How can combined contraception affect lamotrigine treatment?
Medication interactions can run from contraception to another treatment. Estrogen-containing combined oral contraceptives can substantially lower lamotrigine concentrations, potentially impairing seizure control. CDC assigns category 3 to combined oral contraception with lamotrigine monotherapy, with important clarification about other antiseizure regimens. Starting, stopping or cycling estrogen can change exposure, so medication review should precede changes. Distinguish this interaction from enzyme induction that primarily reduces contraceptive hormone concentrations.
Apply it
A patient controlled on lamotrigine monotherapy develops breakthrough seizures after starting a combined pill. Recognize a possible fall in lamotrigine exposure and coordinate antiseizure and contraceptive management rather than simply increasing contraceptive estrogen.
Common pitfall: Lamotrigine should not be treated as another carbamazepine-like inducer. The clinically important direction of interaction here is estrogen lowering the antiseizure drug concentration.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives
7.When do uterine fibroids prevent appropriate IUD placement?
Fibroids alone do not make an IUD unacceptable. The decisive anatomical question is whether distortion makes the uterine cavity incompatible with proper placement. U.S. MEC classifies such cavity distortion as category 4 for both copper and levonorgestrel IUDs. Assess location and cavity shape rather than relying on fibroid size or the diagnosis alone. A non-distorting fibroid and an intracavitary lesion that prevents correct positioning represent different contraceptive decisions.
Apply it
Two patients have fibroids: one has a normal cavity contour, while the other's submucosal lesion markedly distorts the cavity. Evaluate IUD suitability separately instead of excluding both patients because their diagnostic labels match.
Common pitfall: The presence of any fibroid is not the contraindication. Conversely, choosing a smaller device does not establish safe placement in an incompatible, distorted cavity.
8.How should immediate postpartum IUD expulsion risk be discussed?
Immediate postpartum IUD placement can provide contraception before discharge and avoid loss of access at a later visit. Its expulsion risk is higher than interval placement, which may reduce ongoing protection if expulsion goes unrecognized. Counseling should present that tradeoff alongside patient preferences and follow-up access. Higher expulsion risk does not by itself mean immediate placement is medically unacceptable; postpartum sepsis is a separate contraindication requiring a different decision.
Apply it
A patient expects difficulty attending a postpartum visit and prefers an IUD before discharge. Discuss the increased chance of expulsion, signs of possible expulsion and access to assessment or replacement before obtaining informed consent.
Common pitfall: Do not describe immediate postpartum placement as equally likely to remain in place as interval insertion, or treat expulsion risk as equivalent to postpartum infection.
9.When can STI screening occur on the day of IUD placement?
A patient who needs gonorrhea or chlamydia screening can generally be screened at IUD placement without delaying insertion. The distinction is between risk requiring screening and known current infection: current purulent cervicitis, gonorrhea or chlamydia precludes initiating an IUD. History and examination should identify those findings. Screening practices should follow current recommendations, but waiting for a negative result is not routinely necessary in an otherwise appropriate, asymptomatic candidate.
Apply it
An asymptomatic patient due for chlamydia screening requests same-day contraception. With no purulent cervicitis or known infection and pregnancy reasonably excluded, collect the indicated test and proceed with the desired IUD placement.
Common pitfall: Treating a screening indication as proof of infection creates unnecessary delay. Known current cervicitis or infection, however, should not be dismissed as merely a pending screening issue.
10.What bleeding changes are expected with a copper IUD?
Copper IUD users may experience spotting and heavier or prolonged bleeding, especially during the first three to six months. Anticipatory counseling helps patients interpret expected changes without dismissing symptoms that warrant evaluation. New heavy bleeding after a previously stable pattern should prompt consideration of pregnancy, displacement, infection or uterine pathology when clinically indicated. Short courses of NSAIDs during bleeding may help eligible patients, while removal remains available whenever the patient prefers.
Apply it
A patient reports heavier periods during the second month of copper IUD use but no warning symptoms. Discuss the expected early pattern, assess the impact and offer an appropriate short NSAID course or removal according to preference.
Common pitfall: Expected early bleeding is not a reason to minimize severe symptoms. A late change after months of stability deserves a different assessment from initial adjustment.
11.How should bleeding and amenorrhea with a levonorgestrel IUD be interpreted?
Levonorgestrel IUDs commonly cause spotting or light bleeding during the first three to six months, followed by less bleeding; amenorrhea can occur. Heavy or prolonged bleeding is uncommon and may justify evaluation for another cause. Amenorrhea itself requires no treatment, although pregnancy assessment is appropriate when clinically indicated, particularly with an abrupt change. Explain expected patterns and offer continued use or removal according to the patient's goals rather than prescribing unnecessary treatment.
Apply it
A patient with a levonorgestrel IUD gradually stops having periods and feels well. Explain that reduced bleeding can be expected, assess whether pregnancy testing is indicated and ask whether the pattern is acceptable.
Common pitfall: Do not assume amenorrhea means blood is accumulating in the uterus. Equally, do not attribute new heavy bleeding automatically to an established levonorgestrel IUD.
12.When can a copper IUD provide emergency contraception?
CDC recommends copper IUD placement within five days of the first episode of unprotected intercourse for emergency contraception. When ovulation can be estimated, placement may occur more than five days after intercourse if it is no more than five days after ovulation. It also supplies ongoing contraception. Eligibility still requires assessing pregnancy and IUD contraindications; the emergency indication does not override current infection or an incompatible uterine cavity.
Apply it
A patient presents four days after a single episode of unprotected intercourse and wants ongoing nonhormonal contraception. If otherwise eligible, offer a copper IUD as emergency contraception and explain its continued contraceptive role.
Common pitfall: Counting only from the most recent intercourse can miss earlier pregnancy risk. Apply the first-episode timing rule and assess any additional exposure carefully.
13.Why delay hormonal contraception after ulipristal emergency contraception?
Ulipristal has antiprogestin activity that delays ovulation. Starting a progestin-containing contraceptive too soon can reduce that ovulation-delaying effect. CDC advises starting or resuming hormonal contraception no sooner than five days after ulipristal, followed by abstinence or barrier use for seven days after starting or until the next menses, whichever comes first. Nonhormonal contraception can begin immediately. Provider-administered hormonal methods require individualized consideration of the interaction and the risk of losing access.
Apply it
A patient takes ulipristal and plans to restart a combined pill that evening. Explain the interaction, schedule hormonal initiation after the five-day interval and provide clear interim and post-initiation barrier instructions.
Common pitfall: Applying levonorgestrel emergency-contraception instructions to ulipristal can undermine efficacy. Both address recent intercourse, but their interactions with ongoing hormonal contraception differ clinically.
14.How can pregnancy be reasonably excluded before contraception?
Pregnancy exclusion combines absence of pregnancy signs or symptoms with a qualifying history, such as being within seven days of normal menses, having no intercourse since the last normal menses or correctly and consistently using reliable contraception. Specific postpartum and postabortion criteria also apply. A negative urine test alone cannot exclude a pregnancy from recent intercourse. Use the CDC checklist to distinguish meaningful reassurance from a test performed before detectable hCG production.
Apply it
A patient has a negative urine pregnancy test two days after unprotected intercourse. Explain that the test cannot exclude pregnancy from that encounter, assess emergency contraception eligibility and use the pregnancy-exclusion checklist to guide initiation.
Common pitfall: A laboratory result is not automatically more informative than timing and history. Very early pregnancy can remain undetectable despite a correctly performed urine test.
CDC How To Be Reasonably Certain that a Patient Is Not Pregnant
15.Which methods can be started when pregnancy remains uncertain?
When pregnancy cannot be reasonably excluded, the benefits of initiating most non-IUD methods generally exceed the risks; CDC supports initiation with a follow-up pregnancy test in two to four weeks. IUD placement should wait until pregnancy can be reasonably excluded because pregnancy with an IUD carries important complications. Offer an interim method rather than leaving the patient without protection. Separately assess recent intercourse for emergency contraception and its method-specific initiation instructions.
Apply it
A patient with uncertain menstrual dates wants an IUD, but recent pregnancy cannot be excluded. Offer a suitable interim method and arrange reassessment, explaining why a same-day implant or pill follows different initiation guidance.
Common pitfall: The quick-start approach is not identical for every method. Extending the non-IUD recommendation to an IUD ignores the consequences of an unrecognized pregnancy with a device.
CDC How To Be Reasonably Certain that a Patient Is Not Pregnant
16.Why does testosterone-associated amenorrhea not establish contraception?
Testosterone therapy can suppress menstruation without reliably preventing ovulation or pregnancy. A person with a uterus and ovaries who has intercourse involving sperm can remain at risk even when amenorrheic. Ask about organs, sexual practices and pregnancy goals without assumptions based on gender identity. Discuss acceptable contraception and explain that testosterone is not a contraceptive. Its potential fetal effects make pregnancy prevention counseling especially relevant when pregnancy is not desired.
Apply it
A transgender man taking testosterone has no periods and assumes contraception is unnecessary. Ask about sperm exposure and reproductive goals, explain that amenorrhea does not guarantee anovulation and offer methods consistent with his preferences.
Common pitfall: Neither gender identity nor absent bleeding establishes pregnancy risk. Base assessment on reproductive anatomy, sexual exposure and contraceptive use while respecting the patient's terminology.
17.When does postpartum thrombosis risk prohibit combined contraception?
The early postpartum period carries increased venous thromboembolism risk, which estrogen-containing contraception can compound. Combined hormonal contraception is U.S. MEC category 4 before 21 days postpartum, including in patients who are not breastfeeding. Later eligibility depends on postpartum interval, breastfeeding and additional thrombotic risk factors. A desire for immediate contraception should trigger discussion of suitable alternatives rather than an estrogen prescription based only on the absence of breastfeeding.
Apply it
A nonbreastfeeding patient requests a combined ring ten days after delivery. Recognize the early postpartum thrombotic restriction and discuss an eligible alternative while planning when combined-method eligibility could be reassessed.
Common pitfall: Nonbreastfeeding status does not erase postpartum thrombosis risk. Avoid substituting a patch or ring when the restriction applies to the entire combined hormonal category.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives
18.Which contraceptive distinction matters with current breast cancer?
Current breast cancer is a hormone-sensitive condition for which hormonal contraceptive methods receive U.S. MEC category 4. The copper IUD is category 1 for the cancer condition itself because it provides contraception without contraceptive hormone exposure. Other eligibility considerations still apply. Distinguish current disease from a remote history, which has separate classifications, and distinguish a family history of breast cancer from the patient's own active malignancy.
Apply it
A patient receiving treatment for current breast cancer requests reversible contraception. Compare nonhormonal options, including a copper IUD if otherwise eligible, and discuss bleeding considerations and personal preferences alongside oncology treatment needs.
Common pitfall: Local levonorgestrel delivery does not make a hormonal IUD category 1 in current breast cancer. Family history alone should not be treated as active disease.
19.How does severe hypertension alter combined-method eligibility?
Combined hormonal contraception is category 4 with systolic pressure at least 160 mm Hg or diastolic pressure at least 100 mm Hg, reflecting increased cardiovascular risk. Accurate measurement and a properly established blood-pressure assessment matter; one reading is insufficient to classify a person as hypertensive. Controlled hypertension and lower hypertensive ranges have their own restrictions. Choose alternatives using their method-specific classifications rather than assuming all hormonal contraception carries the same cardiovascular risk.
Apply it
A patient with repeatedly documented blood pressure of 168/104 mm Hg requests a combined pill. Explain the cardiovascular restriction, address blood-pressure management and compare appropriate alternatives after reviewing other medical conditions and preferences.
Common pitfall: A low estrogen dose does not overcome category 4 hypertension. Conversely, an isolated erroneous measurement should be checked before assigning a chronic hypertension classification.
CDC Appendix D: Classifications for Combined Hormonal Contraceptives
20.How should pregnancy with an IUD in place be assessed?
A pregnancy diagnosed with an IUD requires evaluation for ectopic pregnancy and discussion of the patient's pregnancy goals. If an intrauterine pregnancy will continue, leaving the IUD increases risks including spontaneous and septic abortion and preterm delivery. CDC recommends removal as soon as possible when strings are visible or the device can be retrieved safely from the cervical canal. Nonvisible strings require localization and individualized management rather than blind intrauterine instrumentation.
Apply it
A patient has a confirmed intrauterine pregnancy, wishes to continue it and has visible IUD strings. Explain the risks of retention and removal, then recommend prompt removal using the accessible strings with appropriate counseling.
Common pitfall: Low absolute pregnancy incidence among IUD users does not remove the need to evaluate location once pregnancy occurs. Do not blindly explore for nonvisible strings.
21.When can an IUD remain during pelvic inflammatory disease treatment?
An IUD does not need immediate removal when its user develops pelvic inflammatory disease and wants to continue the method. Start appropriate antibiotics, provide close follow-up and reassess in 48–72 hours. If improvement is absent, continue antibiotics and consider removal. If the patient wants discontinuation, remove the device after antibiotics have begun. This continuation guidance differs from initiating a new IUD in someone with current infection or purulent cervicitis.
Apply it
A stable patient with an existing IUD is diagnosed with PID and prefers to keep it. Begin antibiotics and arrange reassessment within 48–72 hours, explaining when lack of improvement would change the management plan.
Common pitfall: Automatic immediate removal confuses initiation restrictions with continuation management. Keeping the IUD also does not mean minimizing infection or omitting timely antibiotic treatment and reassessment.
Early pregnancy assessmentnot stated
22.What does pregnancy of unknown location actually establish?
Pregnancy of unknown location describes a positive pregnancy test with neither an intrauterine nor an extrauterine pregnancy identified on transvaginal ultrasonography. It is a temporary classification, not a diagnosis of ectopic pregnancy or completed miscarriage. Possible outcomes include an early intrauterine pregnancy, a resolving pregnancy and ectopic pregnancy. Clinical stability, symptoms, risk factors and structured follow-up determine management; the absence of a visible sac alone does not establish the final outcome.
Apply it
A clinically stable patient has positive hCG and an ultrasound showing no definite pregnancy location. Explain the PUL classification, discuss possible outcomes and establish a follow-up plan rather than declaring an ectopic pregnancy.
Common pitfall: An empty uterus is not synonymous with ectopic pregnancy. Conversely, calling a pregnancy too early to see must not remove ectopic precautions or follow-up.
23.When can an undesired PUL be treated without awaiting sac visualization?
SFP supports immediate medication or procedural management for selected asymptomatic patients with an undesired PUL who have low ectopic risk and a clear plan to establish pregnancy resolution. A baseline quantitative hCG is important when medication management is chosen. The decision combines pregnancy preference, clinical assessment and ability to complete follow-up. Immediate treatment does not mean that mifepristone and misoprostol treat ectopic pregnancy or that location-related risk has disappeared.
Apply it
An asymptomatic patient with an undesired PUL has no identified ectopic risk factors and can complete serial hCG testing. Discuss immediate treatment options with explicit resolution follow-up rather than requiring sac visualization in every case.
Common pitfall: Do not transfer minimal-follow-up protocols for documented intrauterine abortion to a known PUL. The unresolved location creates an additional obligation to demonstrate resolution.
24.How is resolution assessed after medication treatment of a PUL?
For medication management of an undesired PUL, SFP recommends a baseline quantitative hCG and follow-up demonstrating an appropriate decline. Resolution criteria include at least a 50% decrease 48–72 hours after misoprostol, or at least an 80% decrease seven days after mifepristone or 5–10 days after misoprostol. Interpret the percentage using the correct baseline and time anchor. Inadequate decline requires further evaluation; bleeding alone cannot establish pregnancy resolution.
Apply it
Baseline hCG is 1,000 IU/L and falls to 420 IU/L 72 hours after misoprostol. Calculate a 58% decline, recognize that it meets the specified early decline criterion and still review symptoms.
Common pitfall: Using the wrong medication date can misclassify a trend. A falling value below the required threshold is not automatically sufficient reassurance against persistent or ectopic pregnancy.
25.How should an inconclusive very early aspiration be followed?
After aspiration at very early gestation, absence of identified chorionic villi and a gestational sac leaves pregnancy resolution uncertain. SFP recommends additional assessment, including serial quantitative hCG when appropriate. Using the procedure-day baseline, declines greater than 50% at 24 hours, greater than 70% at 48 hours or greater than 80% at approximately 72 hours support resolution. The thresholds are time-specific; symptoms or an inadequate decline require evaluation for ongoing or ectopic pregnancy.
Apply it
No villi or sac are identified after aspiration. The procedure-day hCG of 800 IU/L falls to 200 IU/L at 48 hours, a 75% decline that exceeds the corresponding resolution threshold.
Common pitfall: An empty aspirate does not prove that the pregnancy was ectopic or that abortion was complete. Do not substitute medication-treatment thresholds for aspiration follow-up thresholds.
26.Why cannot a single hCG value determine pregnancy location?
hCG reflects trophoblastic activity rather than anatomical location. A single value cannot distinguish an early intrauterine pregnancy, a failing pregnancy and an ectopic pregnancy. Ultrasound findings, serial measurements, symptoms and examination must be interpreted together. Even a falling hCG does not make new severe pain benign. Avoid treating a numerical threshold as definitive proof of ectopic pregnancy when imaging and clinical circumstances leave meaningful uncertainty about location.
Apply it
A patient with a PUL has one hCG result and no pain. Rather than diagnosing ectopic pregnancy from that number alone, combine the ultrasound findings with risk assessment and appropriately timed repeat testing.
Common pitfall: A reassuring laboratory trend cannot override hemodynamic deterioration. Conversely, a single unexpectedly high hCG without a visible sac is not a complete anatomical diagnosis.
RCOG Ectopic Pregnancy · SFP Management of Undesired Pregnancy of Unknown Location and Abortion at Less Than 42 Days of Gestation
27.Which findings suggest a ruptured ectopic pregnancy?
Ectopic pregnancy can rupture and cause life-threatening intra-abdominal bleeding. Severe abdominal pain, shoulder-tip pain, dizziness, collapse and signs of shock are important warning findings, particularly with a positive pregnancy test or unresolved location. Hemodynamic instability demands emergency assessment, resuscitation and urgent surgical management rather than routine serial testing. Vaginal bleeding can be slight despite major internal hemorrhage, so its apparent volume does not reliably indicate the severity of the emergency.
Apply it
A patient followed for PUL develops unilateral pain, shoulder-tip pain and syncope. Treat the presentation as a possible ruptured ectopic emergency and arrange immediate hospital care rather than waiting for scheduled hCG testing.
Common pitfall: Minimal vaginal bleeding does not exclude major hemorrhage. Do not choose outpatient observation or methotrexate for a patient whose presentation suggests rupture and instability.
28.How are expectant, medical and surgical ectopic treatments distinguished?
For a confirmed tubal ectopic pregnancy, UK NICE NG126 provides an explicit treatment-selection framework. These are guideline-specific clinical thresholds, not universal ABOG examination rules. Offer expectant management as an option when the patient is clinically stable and pain-free, the ectopic measures less than 35 mm without a visible heartbeat, serum hCG is at most 1,000 IU/L, and follow-up is reliable. Consider expectant management above 1,000 but below 1,500 IU/L when the remaining criteria are met. Offer systemic methotrexate when there is no significant pain, the ectopic is unruptured and smaller than 35 mm without a visible heartbeat, hCG is below 1,500 IU/L, intrauterine pregnancy has been excluded, follow-up is reliable, and medication contraindications are absent. At the first visit, methotrexate requires a definitive ectopic diagnosis and exclusion of a viable intrauterine pregnancy. At hCG of at least 1,500 but below 5,000 IU/L, offer a choice between methotrexate and surgery if those other eligibility criteria are satisfied; explain the increased likelihood of further intervention after methotrexate. NICE recommends first-line surgery for significant pain, a mass measuring at least 35 mm, a visible fetal heartbeat, hCG of at least 5,000 IU/L, or inability to return for methotrexate follow-up. Surgery is also appropriate when methotrexate is unacceptable to the patient. Rupture or hemodynamic instability requires emergency surgical management regardless of hCG or mass size.
Apply it
A stable, pain-free patient has a confirmed 24-mm tubal ectopic without a heartbeat, hCG of 800 IU/L, and reliable follow-up. Offer expectant management as an option. Under NICE, repeat hCG on days 2, 4 and 7 after baseline; if each value falls at least 15% from the preceding value, continue weekly until below 20 IU/L. A smaller decline, plateau or rise requires clinical review and reassessment of management. Contrast a patient with the same reassuring symptoms and imaging but hCG of 2,800 IU/L, no intrauterine pregnancy, and no methotrexate contraindication: offer shared choice between methotrexate and surgery. If hCG instead measures 5,200 IU/L, recommend first-line surgery under this framework. New severe pain or collapse overrides an earlier conservative plan and requires urgent assessment for rupture.
Common pitfall: Small size alone does not establish methotrexate eligibility. Obtain baseline blood count, renal function and liver tests. RCOG Green-top Guideline No. 21 lists medication contraindications including breastfeeding, methotrexate hypersensitivity, chronic liver disease, pre-existing blood dyscrasia, active pulmonary disease, immunodeficiency and peptic ulcer disease; it also excludes patients with an intrauterine pregnancy, hemodynamic instability or inability to complete follow-up. These criteria are detailed in [RCOG Green-top Guideline No. 21, Appendices II–III](https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.14189). After methotrexate, NICE recommends hCG measurements on days 4 and 7, followed by weekly testing until negative; plateauing or rising values require reassessment for additional treatment. Do not confuse this schedule with expectant-management monitoring or assume that an injection establishes resolution. Give explicit emergency instructions for severe abdominal pain, shoulder-tip pain or collapse. The tubal selection thresholds above should not be automatically applied to other ectopic implantation sites.
RCOG Ectopic Pregnancy · Management of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE
29.Why is hCG follow-up necessary after salpingotomy?
Salpingotomy removes an ectopic pregnancy while preserving the fallopian tube, but trophoblastic tissue may remain. Serial hCG follow-up is therefore needed to detect persistent pregnancy tissue and determine whether additional methotrexate or surgery is necessary. This differs from assuming that visible surgical removal guarantees complete resolution. The choice between salpingotomy and salpingectomy also considers the condition of the other tube and future fertility goals, alongside immediate surgical findings.
Apply it
After tube-preserving ectopic surgery, a patient feels well and wants to cancel laboratory follow-up. Explain that persistent trophoblast may initially be asymptomatic and that hCG monitoring determines whether further treatment is needed.
Common pitfall: Symptom improvement does not establish trophoblastic clearance. Follow-up expectations after salpingotomy should not be casually replaced with those used after complete removal of the affected tube.
30.When can early pregnancy loss management reflect patient preference?
For confirmed uncomplicated early pregnancy loss, expectant, medication and vacuum aspiration approaches may be appropriate depending on the clinical circumstances and patient preference. They differ in predictability, timing, bleeding and need for subsequent intervention. Infection, major hemorrhage or instability changes the decision and can require urgent evacuation and treatment. Confirm the diagnosis before acting when viability remains uncertain; a preference-sensitive management discussion presupposes a sufficiently established diagnosis and clinical stability.
Apply it
A stable patient with confirmed early pregnancy loss has no infection or heavy bleeding and wants the most predictable completion. Discuss vacuum aspiration alongside medication and expectant management, explaining the differences in timing and experience.
Common pitfall: Do not present one approach as obligatory for every stable patient. Preference does not, however, make observation appropriate when infection or dangerous hemorrhage requires treatment.
31.How does suspected molar pregnancy change evacuation planning?
Gestational trophoblastic disease includes abnormal trophoblastic proliferations that require diagnosis, appropriate uterine evacuation and subsequent hCG surveillance. Suspected molar pregnancy warrants assessment for complications such as bleeding, anemia, hypertension and hyperthyroidism, with care resources matched to severity. Suction evacuation is a principal fertility-preserving treatment for a hydatidiform mole, and pathological examination establishes the diagnosis. The plan must extend beyond removing uterine contents because persistent disease can occur after evacuation.
Apply it
A patient with ultrasound findings suspicious for a mole has tachycardia and marked vomiting. Assess bleeding and possible thyroid complications, organize appropriately supported evacuation and ensure tissue diagnosis and a postevacuation hCG surveillance plan.
Common pitfall: Do not treat evacuation as the endpoint of molar care. Missing systemic complications before the procedure or failing to arrange surveillance can overlook substantial risk.
NCI Gestational Trophoblastic Disease Treatment (PDQ), Health Professional Version
32.Which hCG patterns and surveillance schedules guide care after molar evacuation?
Serial quantitative hCG detects postmolar gestational trophoblastic neoplasia. FIGO's 2026 diagnostic criteria define a plateau as less than 10% change across four measurements over at least three weeks and a qualifying rise as more than 10% across three consecutive weekly measurements over at least two weeks. Histological choriocarcinoma also establishes GTN. FIGO's 2025 management guidance recommends hCG every one to two weeks until normalization; if a rise or plateau appears during two-week sampling, obtain the next sample after one week. After partial mole, obtain one confirmatory hCG one month after normalization. After complete mole, monitor monthly for six months after normalization. These are FIGO clinical recommendations, rather than ABOG examination rules. Effective contraception prevents a new pregnancy from obscuring surveillance.
Apply it
After complete mole evacuation, hCG values on days 1, 7, 14 and 21 are 1,000, 1,020, 990 and 1,010 IU/L. This plateau requires GTN evaluation rather than waiting for normalization. After spontaneous normalization without GTN, continue monthly monitoring for six months; a partial mole instead requires a confirmatory test one month after normalization.
Common pitfall: Do not diagnose a qualifying plateau from two measurements or apply the shorter partial-mole schedule to complete mole. Unexpected low hCG also warrants consideration of new pregnancy and assay interference. FIGO's numerical diagnostic definitions are described in its 2026 criteria, doi:10.1002/ijgo.71229.
NCI Gestational Trophoblastic Disease Treatment (PDQ), Health Professional Version · IJGO-171-78.PMC12411817.pdf
33.When should persistent low serum hCG raise concern for assay interference?
Heterophile antibodies can interfere with serum hCG immunoassays and produce a false-positive result, sometimes called phantom hCG. Suspect interference when persistent low serum values conflict with clinical findings, especially when urine testing is negative. Laboratory evaluation can include another assay platform, serial dilution and antibody-blocking methods. Interpret urine sensitivity and the serum concentration together. Confirming the explanation can prevent unnecessary chemotherapy or surgery for a biochemical result that does not represent trophoblastic disease.
Apply it
A well patient has repeatedly low positive serum hCG, negative urine testing and no compatible imaging findings. Ask the laboratory to investigate assay interference with alternative methods before committing to treatment for persistent trophoblastic disease.
Common pitfall: Serum–urine discordance is a clue, not proof by itself. Very low true hCG may fall below a urine assay's detection threshold and needs careful interpretation.
NCI Gestational Trophoblastic Disease Treatment (PDQ), Health Professional Version
Abortionnot stated
34.How do medication-abortion mechanisms translate into a defined early regimen and response to failure?
Mifepristone antagonizes progesterone receptors and increases uterine responsiveness to prostaglandins; misoprostol is a prostaglandin E1 analogue that promotes cervical change and uterine contractions. For intrauterine pregnancy through 70 days, the FDA-labeled regimen is mifepristone 200 mg orally followed 24–48 hours later by misoprostol 800 micrograms buccally. The label calls for completion assessment approximately 7–14 days after mifepristone. Ongoing pregnancy is managed with uterine aspiration under the label. If expulsion is incomplete but pregnancy is no longer ongoing, a further 800-microgram buccal misoprostol dose is a labeled option, with reassessment approximately seven days later; aspiration is another option. Hemorrhage or infection requires urgent assessment. Other evidence-based regimens may use different routes, intervals or gestational ranges; distinguish those protocols from this labeled indication.
Apply it
A patient with a confirmed intrauterine pregnancy at 63 days receives mifepristone 200 mg orally and takes misoprostol 800 micrograms buccally 24–48 hours later. At follow-up, continuing embryonic cardiac activity calls for management of ongoing pregnancy, including aspiration under the FDA label, rather than assuming bleeding establishes success.
Common pitfall: Do not extrapolate the through-70-day labeled regimen unchanged to later gestations. Distinguish ongoing pregnancy from incomplete expulsion without ongoing pregnancy because the labeled responses differ.
FDA Mifeprex Prescribing Information, Revised January 2023 · WHO Clinical Practice Handbook for Quality Abortion Care
35.Why does suspected ectopic pregnancy change medication abortion care?
Mifepristone with misoprostol does not treat ectopic pregnancy, and confirmed or suspected ectopic pregnancy is a contraindication in FDA labeling. Symptoms or findings that raise ectopic concern require appropriate evaluation rather than assuming medication-induced bleeding will settle the question. Distinguish suspected ectopic pregnancy from a low-risk asymptomatic PUL, for which SFP describes selected immediate-treatment pathways with explicit hCG follow-up. The key distinction is assessed ectopic risk, not ultrasound visibility alone.
Apply it
A patient requesting medication abortion has significant unilateral pain and a suspicious adnexal finding. Evaluate for ectopic pregnancy and select location-appropriate care rather than prescribing routine medication abortion as treatment for the suspected ectopic.
Common pitfall: Bleeding after misoprostol does not prove an intrauterine pregnancy has resolved. Avoid equating a low-risk PUL pathway with treatment of a clinically suspected ectopic pregnancy.
FDA Questions and Answers on Mifepristone · SFP Management of Undesired Pregnancy of Unknown Location and Abortion at Less Than 42 Days of Gestation
36.Which postmedication symptoms suggest serious infection?
Transient chills, gastrointestinal symptoms and fever can occur around misoprostol use, but persistent or delayed systemic illness requires assessment. FDA labeling highlights sustained fever, severe abdominal pain and malaise or gastrointestinal discomfort lasting more than 24 hours after misoprostol as warning findings. Serious infection can present without fever. Interpret timing, persistence and overall condition rather than using temperature alone to reassure a patient who feels increasingly unwell after treatment.
Apply it
A patient reports worsening weakness, abdominal discomfort and persistent diarrhea more than a day after misoprostol, despite no measured fever. Arrange prompt evaluation for serious complications instead of attributing everything to expected medication effects.
Common pitfall: Absence of fever does not exclude serious infection. Conversely, brief chills immediately after misoprostol are different from delayed, persistent or worsening systemic illness.
37.When should bleeding after medication abortion trigger urgent contact?
Medication abortion normally causes bleeding and cramping, but very heavy or prolonged bleeding needs assessment. FDA labeling advises immediate contact for bleeding that soaks two thick full-size sanitary pads per hour for two consecutive hours. Symptoms such as faintness, marked weakness or hemodynamic compromise can justify urgent care even without meeting a pad-count threshold. Counseling should distinguish expected expulsion bleeding from possible hemorrhage and give an accessible contact and emergency plan.
Apply it
A patient reports soaking two large pads each hour for two hours and feeling lightheaded. Direct urgent assessment rather than asking the patient to wait for routine follow-up or to estimate whether tissue has passed.
Common pitfall: Pad counts are practical warning instructions, not a requirement before seeking care. Syncope or instability should not be discounted because bleeding volume is difficult to measure.
38.Which placental findings raise concern for severe procedural hemorrhage?
A uterine scar combined with complete placenta previa after the first trimester should prompt evaluation for placenta accreta spectrum. Abnormally adherent or invasive placentation can prevent normal placental separation and cause major hemorrhage. SFP recommends identifying high-risk patients before the procedure and considering referral to a higher-acuity setting. The discriminating combination is placental location plus prior uterine surgery, rather than assuming that every prior cesarean alone predicts the same risk.
Apply it
A patient seeking second-trimester abortion has two prior cesareans and complete previa over the scar. Arrange evaluation for accreta spectrum and plan care where major hemorrhage can be managed before proceeding.
Common pitfall: Do not interpret a reassuring current hemoglobin as evidence against accreta-related hemorrhage risk. Preprocedural anatomy can predict risk before bleeding or instability develops.
39.How should hemorrhage risk determine the abortion care setting?
Care location should match the anticipated complication risk and the resources needed if that complication occurs. Important considerations include abnormal placentation, coagulopathy, gestational age, serious comorbidity and access to blood products, anesthesia, embolization or surgery. SFP recommends considering referral for patients at high hemorrhage risk. Referral planning is most useful before treatment begins, with explicit communication of the suspected mechanism and required capabilities rather than a nonspecific label of complex care.
Apply it
A patient with suspected abnormal placentation is scheduled at a site without transfusion or surgical backup. Arrange care in a setting with the required hemorrhage resources and communicate the anatomical concern before the procedure.
Common pitfall: Current stability does not guarantee that a low-resource setting is appropriate. Conversely, a risk factor should be interpreted specifically rather than automatically requiring identical escalation for every patient.
40.How is abortion-related hemorrhage approached systematically?
SFP organizes hemorrhage management around assessment and examination, uterine massage and medical therapy, resuscitative measures with laboratory evaluation and possible reaspiration or balloon tamponade, and escalation to embolization or surgery. These actions may overlap when bleeding is severe. Examination distinguishes atony, retained tissue, cervical injury and other mechanisms so treatment targets the cause. Resuscitation should proceed alongside source assessment rather than waiting until every diagnostic possibility has been resolved.
Apply it
A patient develops brisk bleeding immediately after aspiration. Begin assessment and resuscitative support while examining uterine tone, the cervix and possible retained tissue, then direct treatment to the identified source rather than repeating one intervention blindly.
Common pitfall: A sequential algorithm is not permission to delay resuscitation. Repeated uterotonics alone will not correct a cervical laceration, perforation or substantial retained tissue.
41.Why must hemorrhage prophylaxis be distinguished from atony treatment?
Evidence for preventing hemorrhage does not automatically establish benefit for every drug given before a procedure. SFP supports oxytocin prophylaxis for D&E in relevant settings but reports that prophylactic methylergonovine at 20–24 weeks can worsen bleeding outcomes. Treatment of established atony is a separate question involving uterine massage and appropriate uterotonics. The timing, indication and patient contraindications determine whether a drug is appropriate; being a uterotonic does not make all prophylactic uses beneficial.
Apply it
A team proposes routine methylergonovine before every 22-week D&E because it contracts the uterus. Review the evidence against that prophylactic use and distinguish it from selecting treatment once clinically significant atony occurs.
Common pitfall: Do not infer prophylactic effectiveness from a drug's contractile mechanism or its use in another obstetric context. Preventive and therapeutic indications require separate evidence.
42.When is balloon tamponade appropriate after abortion?
SFP recommends uterine balloon tamponade for persistent bleeding caused by atony or lower uterine segment bleeding when retained tissue and hematometra are not suspected. The balloon provides mechanical compression after initial measures fail. Suspected retained tissue instead supports reaspiration when appropriate. Continue resuscitation and monitor the response; tamponade is not definitive treatment for every cause of hemorrhage, and ongoing bleeding may require embolization or surgery depending on the source and available resources.
Apply it
Bleeding persists despite massage and uterotonics; examination and ultrasound support an empty cavity, intact cervix and uterine atony. Use balloon tamponade while maintaining resuscitation and preparing escalation if bleeding continues.
Common pitfall: An intrauterine balloon should not substitute for removing retained tissue or repairing a laceration. Establish a plausible compressible bleeding source before relying on tamponade.
43.Which findings favor cervical injury over uterine atony?
Persistent bleeding despite a firm uterus should prompt inspection for a cervical laceration and assessment for other non-atonic sources. A visible cervical tear requires source-directed hemostasis, which can include pressure, topical measures or suturing depending on size and location. Repeated uterotonics do not repair disrupted cervical vessels. Severe or high lacerations can involve more substantial vascular injury, requiring escalation and consideration of associated uterine or extrauterine damage.
Apply it
After D&E, the uterus is firm but bleeding continues. Speculum examination identifies an actively bleeding cervical tear. Treat the tear directly while supporting circulation rather than escalating uterotonics as the sole intervention.
Common pitfall: Firm uterine tone does not exclude serious hemorrhage. Avoid labeling all postabortion bleeding as atony before inspecting the cervix and assessing other possible sources.
44.Why is cervical preparation important for D&E at 20–24 weeks?
Cervical preparation reduces procedural difficulty and the risk of cervical and uterine injury during later D&E. SFP recommends at least one day of preparation with osmotic dilators at 20–24 weeks; overnight dilators alone are sufficient for most procedures in this interval. Dilators gradually expand by absorbing fluid, creating controlled cervical dilation. Gestational age, anatomy and procedural circumstances influence planning. Same-day approaches require appropriate expertise and should not be treated as universally equivalent substitutes.
Apply it
A patient is scheduled for D&E at 22 weeks. Plan overnight osmotic dilators rather than relying on forceful mechanical dilation immediately before evacuation, and explain how preparation improves procedural conditions and safety.
Common pitfall: A medication-only preparation strategy is not automatically equivalent to overnight dilators at 20–24 weeks. Do not generalize earlier-gestation preparation practices to this interval.
SFP Cervical Preparation for Dilation and Evacuation at 20–24 Weeks
45.How does adjunctive mifepristone affect later D&E preparation?
SFP recommends considering mifepristone at osmotic dilator placement before D&E at 20–24 weeks because it can make the procedure subjectively easier without increasing side effects. It may provide benefit comparable to an additional day of serial dilators in some circumstances. This is adjunctive preparation, not evidence that dilators can routinely be omitted. Adjunctive misoprostol has a different evidence profile, including more pain and nausea compared with mifepristone in the cited guidance.
Apply it
A clinician wants to improve preparation for a 23-week D&E without automatically scheduling two days of dilator placement. Consider adjunctive mifepristone with overnight dilators, using the gestational-age-specific evidence to explain the plan.
Common pitfall: Do not translate an adjunct's benefit into permission to omit the primary preparation. Mifepristone and misoprostol also should not be assumed to have identical side-effect profiles.
SFP Cervical Preparation for Dilation and Evacuation at 20–24 Weeks
46.When are prophylactic antibiotics indicated for abortion or pregnancy loss?
SFP recommends universal antibiotic prophylaxis for procedural abortion and procedural management of pregnancy loss, with antibiotics initiated before instrumentation. Routine prophylaxis is not recommended for medication abortion or medication management of pregnancy loss because infection rates are low and unnecessary antibiotics have harms. Prophylaxis differs from treatment of a diagnosed infection, which requires an appropriate therapeutic regimen. The route of pregnancy management, rather than the pregnancy's intendedness, determines this preventive distinction.
Apply it
Two patients choose aspiration and medication management for early pregnancy loss. Plan pre-instrumentation prophylaxis for aspiration, while avoiding routine antibiotics for the uncomplicated medication pathway unless a separate infection indication is present.
Common pitfall: A prophylactic dose does not treat established PID or another diagnosed infection. Do not give routine medication-abortion antibiotics simply because procedural abortion prophylaxis is recommended.
SFP Prevention of Infection After Abortion and Pregnancy Loss
47.How should STI testing and treatment be coordinated with abortion?
Indicated gonorrhea and chlamydia testing should be integrated into abortion care without making routine completion contingent on receiving results. SFP recommends treating known infection or high clinical suspicion while avoiding unnecessary abortion delays for testing or treatment. STI treatment and procedural prophylaxis serve different purposes and may both be indicated. Severe infection or septic abortion changes clinical urgency and management; it should not be confused with an otherwise stable patient awaiting screening results.
Apply it
An asymptomatic patient needs chlamydia screening before aspiration and can be contacted reliably. Collect the test, provide indicated procedural prophylaxis and proceed without waiting for the result, arranging therapeutic treatment if the test is positive.
Common pitfall: Waiting for every screening result can create avoidable barriers. Conversely, routine procedural prophylaxis should not be assumed to eradicate a known infection requiring full treatment.
SFP Prevention of Infection After Abortion and Pregnancy Loss
48.How should multimodal pain management be planned for procedural abortion?
Pain planning should combine explanation, supportive care and appropriate pharmacological methods rather than treating distress as inevitable. NSAIDs and a paracervical block address different components of procedural pain; conscious sedation may be offered where available and appropriate. A paracervical block does not reliably remove all uterine cramping, and anxiety support does not replace analgesia. Match sedation to the patient's preferences, comorbidities and monitoring resources instead of routinely requiring general anesthesia for every procedure.
Apply it
A patient undergoing aspiration wants to remain awake but fears pain. Discuss an NSAID, paracervical block and supportive measures, with available sedation options and realistic expectations about pressure and cramping during the procedure.
Common pitfall: Reassurance alone is not adequate analgesia. Equally, a local block should not be promised to eliminate every sensation or used to dismiss a patient's additional needs.
49.When is routine follow-up unnecessary after uncomplicated abortion?
WHO states that routine follow-up is not medically necessary after an uncomplicated surgical or medication abortion when patients have adequate information about warning symptoms and access to care. An optional follow-up visit can address concerns and other needs. This principle does not remove a required plan to assess medication-abortion success or resolve known diagnostic uncertainty. A PUL, ongoing symptoms or suspected complication requires condition-specific assessment rather than automatic application of an uncomplicated-care pathway.
Apply it
A patient has an uncomplicated aspiration with completion assessed and no concerning symptoms. Provide clear return precautions and an optional visit rather than insisting on routine ultrasound solely because an abortion occurred.
Common pitfall: No mandatory routine visit does not mean no safety information or contact access. Do not apply uncomplicated follow-up guidance to unresolved location or suspected ongoing pregnancy.
WHO Clinical Practice Handbook for Quality Abortion Care · SFP Management of Undesired Pregnancy of Unknown Location and Abortion at Less Than 42 Days of Gestation
50.How should pregnancy tests and symptoms be interpreted when assessing medication-abortion completion?
Bleeding and passage of tissue do not independently prove completion. High-sensitivity urine pregnancy tests can remain positive for up to five weeks after successful medication abortion because residual hCG remains detectable; an early positive result alone does not establish ongoing pregnancy. Low-sensitivity urine tests detect higher hCG concentrations and can be used at the specified time within a validated follow-up protocol. Quantitative serum hCG allows comparison with a baseline to assess decline rather than giving only a positive or negative result. Persistent pregnancy symptoms or minimal or absent bleeding warrant evaluation for ongoing pregnancy and, when indicated, ectopic pregnancy. Ultrasound can assess a persistent gestational sac or ongoing pregnancy; endometrial thickness alone should not determine intervention. Known PUL requires its separate quantitative resolution pathway.
Apply it
Three weeks after treatment of a documented intrauterine pregnancy, a patient feels well, had expected bleeding and has a positive high-sensitivity home test. Explain residual hCG and arrange interpretation or repeat assessment using the follow-up plan rather than diagnosing failure from the test alone. Persistent nausea with almost no bleeding instead warrants prompt completion assessment.
Common pitfall: Do not treat high- and low-sensitivity urine tests as interchangeable. A positive high-sensitivity test can persist after success, but persistent symptoms, concerning pain or inadequate quantitative hCG decline must not be dismissed as residual hormone.
WHO Clinical Practice Handbook for Quality Abortion Care · SFP Management of Undesired Pregnancy of Unknown Location and Abortion at Less Than 42 Days of Gestation
51.Why discuss contraception before the first postabortion menstrual period?
Ovulation can return soon after abortion and before the next menstrual period, so waiting for bleeding to resume can leave a pregnancy-risk interval. Offer contraception according to the patient's goals without making its acceptance a condition of abortion care. Many methods can begin immediately, while IUD timing depends on completion and clinical circumstances. Immediate IUD placement is inappropriate after septic abortion. Explain method-specific timing and backup needs rather than providing a universal instruction to wait for menses.
Apply it
A patient plans to restart contraception only when the next period occurs. Explain that ovulation can precede that period, discuss desired methods and arrange appropriately timed initiation without pressuring acceptance of any method.
Common pitfall: Absence of a postabortion period does not imply absence of fertility. Immediate access should support choice rather than become an expectation that contraception must be accepted.
Research, health policy and advocacynot stated
52.How is a risk ratio calculated and interpreted?
A risk ratio compares the probability of an outcome in an exposed group with that in an unexposed or comparison group. Calculate each risk using its own population at risk, then divide exposed risk by comparison risk. A ratio above one indicates higher observed risk, and below one indicates lower risk. Interpretation requires the outcome definition, follow-up period and study design. An association alone does not establish that the exposure caused the difference.
Apply it
In a fictional cohort, complications occur in 12 of 300 exposed patients and 6 of 300 comparison patients. Risks are 4% and 2%, giving a risk ratio of 2 and a two-percentage-point difference.
Common pitfall: Comparing event counts without denominators can mislead when group sizes differ. A risk ratio of two also does not mean an increase of two percentage points.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
53.Why is the odds ratio appropriate for a case-control study?
Case-control studies select participants by outcome status and compare prior exposures. Because investigators choose the numbers of cases and controls, the sample does not directly reveal population outcome risks. The odds ratio compares exposure odds among cases and controls and is calculated as the cross-product ratio of a two-by-two table. Controls should represent the exposure distribution in the population that produced the cases. A rare outcome can allow the odds ratio to approximate a risk ratio.
Apply it
Researchers sample patients with a rare complication and controls from the same source population. Compare prior exposure using an odds ratio, while checking that control selection was independent of the exposure under study.
Common pitfall: Dividing cases by all sampled participants does not estimate population risk when sampling fixed the case-control ratio. Poorly chosen controls can bias the odds ratio.
CDC Field Epidemiology Manual: Designing and Conducting Analytic Studies
54.What does a confidence interval reveal about an association?
A confidence interval describes statistical uncertainty around an estimate under the analysis assumptions. For ratio measures, one is the null value; for differences, zero is the null. A wide interval signals limited precision and may include clinically important benefit and harm. Including the null does not prove equivalence or no effect. Confidence intervals address sampling uncertainty, not whether selection bias, confounding or measurement error has made the estimate systematically inaccurate.
Apply it
A study reports a complication risk ratio of 0.8 with a 95% confidence interval of 0.3–2.1. Explain that the results are imprecise and compatible with substantial reduction or increase rather than declaring equal safety.
Common pitfall: Statistical nonsignificance is not evidence of equivalence. A narrow confidence interval can still surround a biased estimate if the design or measurement process is flawed.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
55.How can confounding distort a treatment comparison?
Confounding occurs when another factor associated with both the exposure and outcome mixes its effect with the exposure's apparent effect, without lying on the causal pathway being estimated. For example, patients with greater baseline risk may preferentially receive a particular procedure. Stratification or appropriate multivariable adjustment can help address measured confounders; randomization addresses confounding through allocation. A larger sample improves precision but does not by itself remove systematic confounding or residual differences.
Apply it
A referral hospital reports more hemorrhage after one procedure, but its patients also have more advanced gestations. Compare outcomes within gestational-age strata and use an appropriate adjusted analysis before attributing the crude difference to the procedure.
Common pitfall: Adjusting for every available variable is not automatically correct. A mediator on the causal pathway differs from a confounder and can change the question being estimated.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
56.How does selection bias threaten a patient-experience survey?
Selection bias arises when inclusion or participation is related to the exposure and outcome in a way that distorts their relationship. A clinic survey that reaches only patients who return may omit those facing the greatest travel barriers or dissatisfaction. Increasing responses within the same restricted group does not necessarily correct the problem. Define the population of interest, examine who is missing and design sampling or outreach to represent the care experiences being evaluated.
Apply it
A clinic concludes access is excellent from surveys completed only at follow-up visits. Assess whether patients unable to return were excluded and add suitable outreach before generalizing the findings to all patients seeking care.
Common pitfall: A high response rate among attendees does not establish representativeness of all eligible patients. Precision within a selected sample cannot repair systematic exclusion of others.
CDC Field Epidemiology Manual: Designing and Conducting Analytic Studies
57.Which denominator makes a service-access comparison meaningful?
A count becomes an interpretable proportion or rate only when paired with an appropriate denominator. For access evaluation, the denominator should represent the population eligible for or needing the service during a defined period. Total visits, unique patients and the population needing care answer different questions. Compare groups using consistent definitions and consider differences in age or other relevant population characteristics before interpreting an observed difference as an access disparity.
Apply it
One region provides 200 appointments and another 100, but their eligible populations are 20,000 and 5,000. Calculate comparable utilization measures before concluding that the region with more appointments has better population access.
Common pitfall: Raw service volume reflects population size as well as access. A denominator containing repeat visits may also misrepresent how many distinct people obtained needed care.
CDC Field Epidemiology Manual: Describing Epidemiologic Data
58.Why report absolute effects alongside relative effects?
Relative measures describe proportional change, while absolute measures show how much outcome probability changes. The same relative reduction can imply very different benefits when baseline risks differ. Risk difference subtracts comparison risk from intervention risk; its sign depends on group order and outcome definition. For a beneficial reduction, the number needed to treat is the reciprocal of absolute risk reduction expressed as a proportion, provided the comparison and follow-up period support that interpretation.
Apply it
A fictional intervention lowers complications from 4% to 2% over a defined follow-up period. Report a 50% relative reduction and a 2% absolute reduction; the corresponding number needed to treat is 50.
Common pitfall: Using the number 2 rather than 0.02 in the reciprocal calculation gives the wrong result. A number needed to treat also requires a stated outcome and timeframe.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
59.How should reproductive health disparities be described without assuming causation?
Describe disparities using clearly defined populations, outcomes, denominators and time periods, then investigate mechanisms that could produce the differences. Travel, cost, referral systems and appointment availability are potential structural barriers rather than patient character traits. Descriptive data identify where differences occur but cannot alone prove which mechanism caused them. Combine stratified service measures with additional study of barriers and patient experience, protecting against stigmatizing explanations unsupported by the evidence.
Apply it
Rural patients have longer measured waits for abortion appointments than urban patients. Verify comparable definitions and denominators, then investigate travel and scheduling barriers before attributing the difference to patient motivation or a specific policy.
Common pitfall: A group-level difference does not establish an individual's experience or a causal mechanism. Avoid translating descriptive associations into assumptions about preferences, behavior or biological susceptibility.
CDC Field Epidemiology Manual: Describing Epidemiologic Data · ABOG Complex Family Planning competency blueprint
60.How does evidence become an advocacy action with measurable equitable effects?
ABOG competency CFP4.2.D addresses advocacy pathways at institutional, local, state and national levels. Start by defining a barrier with population data and affected patients' accounts. Identify who has authority to change it, involve patients and relevant stakeholders, and present a specific proposal with resources, responsibilities and evaluation measures. Choose the level that controls the barrier: institutional leadership for a clinic rule or budget, local partners for service coordination, or the relevant state or national agency or legislative body for broader policy. Evaluate implementation, patient burden, access and differences between groups. Before-and-after improvement supports monitoring but does not alone prove causation.
Apply it
In a fictional service, patients traveling over two hours miss more appointments, and interviews identify transport cost as a barrier. Patients, community transport partners, schedulers and clinicians co-design a proposal asking the hospital budget committee to fund a six-month travel-support pilot with a named coordinator and simple eligibility process. Track support offered and received, appointment completion among eligible patients, waiting time and reported burden. Compare with baseline and an appropriate comparison service if feasible; stratify results by travel distance, income and language to check equitable reach and revise exclusionary procedures.
Common pitfall: A report describing disparities without a decision-maker or specific request is an incomplete advocacy pathway. Vouchers distributed measure activity; completed care and reduced burden measure access. Seek input from patients who could not attend, and consider concurrent staffing, referral or demand changes before attributing outcomes to the intervention.
CDC Field Epidemiology Manual: Describing Epidemiologic Data · CDC Field Epidemiology Manual: Designing and Conducting Analytic Studies · ABOG Complex Family Planning competency blueprint
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the complete ABOG outline to identify competencies beyond these 60 selections, especially uncommon anatomy, device complications, systemic comorbidities and rare abortion emergencies.
- Separate contraceptive safety, effectiveness, medication interactions and patient preference before choosing a method.
- Practise pregnancy-location reasoning and time-anchored hCG calculations; distinguish medication-PUL follow-up, very early aspiration follow-up and postmolar surveillance.
- Link hemorrhage findings to their source: atony, retained tissue, cervical injury, abnormal placentation or extrauterine injury.
- Distinguish prophylaxis from treatment, screening from diagnosed infection, and uncomplicated follow-up from unresolved diagnostic uncertainty. Rehearse the defined medication regimen and interpret pregnancy tests by sensitivity and timing.
- Interpret research with explicit denominators, absolute effects, uncertainty and confounding. Turn a defined structural barrier into an advocacy proposal directed to the responsible decision-maker, with patient involvement and evaluation of equitable effects.
A practical preparation plan
1. Map the full competency outline
Mark every official task as confident, developing or unstudied. Use the four domains to organize study without assigning unsupported examination percentages. Add focused reading for competencies not developed in this selective guide.
2. Build method-specific decision comparisons
For each contraceptive case, state the patient's goal, relevant U.S. MEC condition, interaction direction and acceptable alternatives. Compare initiation with continuation and distinguish estrogen restrictions from restrictions affecting other hormonal methods.
3. Rehearse early pregnancy pathways
Work through stable PUL, suspected rupture, inconclusive aspiration and postmolar surveillance separately. Calculate hCG percentage changes by hand and label the baseline, medication or procedure date, follow-up interval and action threshold. Distinguish partial- and complete-mole monitoring after normalization.
4. Explain mechanisms and responses aloud
State the population, dose, route and interval for the defined early medication-abortion regimen, then distinguish ongoing pregnancy from incomplete expulsion. For complications, identify the suspected source, immediate support, source-directed treatment and escalation trigger.
5. Complete the independent drills
Answer the 20 questions before reading explanations. Classify each error as a factual gap, missed clinical cue, inappropriate generalization or calculation problem, then revisit the corresponding concept and primary reference.
6. Space recall and practise advocacy
Use the flashcards across several sessions. For research items, write the two-by-two table or denominator before calculating. For clinical items, name the guideline and population before generalizing. For an access barrier, identify the decision-maker, involve affected patients, specify the requested change and choose measures of implementation and equitable effects.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABOG subspecialty-certification blueprint listing
- ABOG Complex Family Planning competency blueprint
- 2026 Subspecialty Qualifying Examination Bulletin
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
- CDC Appendix D: Classifications for Combined Hormonal Contraceptives
- CDC Appendix B: Classifications for Intrauterine Devices
- CDC Summary of U.S. MEC Classifications, 2024
- CDC Intrauterine Contraception
- CDC Emergency Contraception
- CDC How To Be Reasonably Certain that a Patient Is Not Pregnant
- CDC Testosterone Use and Risk for Pregnancy
- SFP Management of Undesired Pregnancy of Unknown Location and Abortion at Less Than 42 Days of Gestation
- RCOG Ectopic Pregnancy
- NCI Gestational Trophoblastic Disease Treatment (PDQ), Health Professional Version
- SFP Management of Hemorrhage at the Time of Abortion
- SFP Hemorrhage Clinical Recommendation: Full Text
- SFP Cervical Preparation for Dilation and Evacuation at 20–24 Weeks
- SFP Prevention of Infection After Abortion and Pregnancy Loss
- WHO Clinical Practice Handbook for Quality Abortion Care
- WHO Abortion Care Guideline, Second Edition
- FDA Questions and Answers on Mifepristone
- FDA Mifeprex Prescribing Information, Revised January 2023
- CDC Field Epidemiology Manual: Analyzing and Interpreting Data
- CDC Field Epidemiology Manual: Designing and Conducting Analytic Studies
- CDC Field Epidemiology Manual: Describing Epidemiologic Data
- Society-of-Family-Planning-clinical-recommendations-Cervical-preparation-for-dilation-and-evacuation-at-2024-weeks-gestation.pdf
- IJGO-171-78.PMC12411817.pdf
- Management of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE
- Placenta Accreta Spectrum | ACOG - College
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.